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Abstract
Purpose The aim of this study was to examine the expres-
sion of ERM (ezrin, moesin) and Rho (RhoA, RhoB and
Cdc42) proteins in breast cancer (BC) patients and to inves-
tigate the relationship between the sub-cellular localisation
of these proteins and clinicopathological characteristics and
patient survival.
Methods The expression and specific sub-cellular distribu-
tion of the ERM/Rho proteins was analysed by immunohis-
tochemistry in a homogeneous group of 85 stage II ductal
BC patients with a follow-up of 15 years.
Results Enhanced immunoreactivity of all analysed proteins
was found to be associated with the presence of lymph node
metastases (ezrin, P=0.047, moesin, P=0.038, RhoA, P=
0.024, RhoB, P=0.004 and Cdc42, P=0.047). Nuclear
localisation of ezrin was found to correlate with the presence
of lymph nodes metastases (P=0.004) and with histological
de-differentiation (P=0.015). In contrast, we found that the
nuclear topography of RhoA and Cdc42, and the perinuclear
localisation of RhoB, were strongly associated with a lack of
nodal metastases (P=0.008, P=0.048, P=0.001, respective-
ly), whereas a decreased reactivity of RhoA in the stromal
compartment of BC tumours was associated with the pres-
ence of lymph node metastases (P=0.011). No relationship
was observed between ERM/Rho protein expression and
oestrogen receptor (ER), progesterone receptor (PgR) or
HER-2 reactivity in the BC cells. Also, ERM/Rho protein
expression did not predict patient survival, but RhoB over-
expression in the stromal compartment of the tumours was
found to be associated with a better prognosis (P=0.0106).
Conclusions The ERM/Rho immunoprofile and the assess-
ment of its specific sub-cellular localisation may be instru-
mental for the prediction of lymph node metastases in ductal
BC patients.
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1 Introduction
Breast cancer (BC) continues to be a major cause of morbidity
and mortality, and it is one of the most common causes of
cancer death in women world-wide. In 2008, more than 1.38
million new BC cases were diagnosed, leading to the death of
approximately 500,000 individuals [1]. The standard method
of BC treatment is multimodality management: endocrine
therapy, surgery, radiotherapy, chemotherapy and molecularly
targeted therapy. Conventional prognostic and predictive fac-
tors include disease stage (tumour size, nodal status and
presence of distant metastases) [2], expression of oestrogen
and progesterone receptors (ER and PgR, respectively) [3],
immunohistochemical/molecular status of HER-2 [4], and Ki-
67 expression. Detailed gene expression analyses have led to
the recognition of five fundamentally different subtypes of
BC. However, since gene expression analysis of BC tumour
material is not always feasible in clinical practice, a simplified
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classification system was recently recommended by the St.
Gallen International Expert Consensus group. The main ele-
ments of this classification system include an immunohisto-
chemical evaluation of ER and PgR status, assessment of
over-expression and/or genomic amplification of HER-2,
and the Ki-67 labelling index, which is a marker for cellular
proliferation [5].
Ezrin, radixin and moesin, collectively known as ERM
proteins, exhibit tissue-specific expression patterns. Ezrin ex-
pression is predominantly observed in epithelial cells, whereas
moesin is expressed in endothelia, and radixin in hepatocytes
[6]. ERM proteins function as structural and regulatory cross-
linkers organising membrane-cytoskeleton-associated com-
plexes. As such, they play a crucial role in the control of cell
morphology. They also regulate a wide range of cellular
activities including polarity, motility, adhesion and survival,
all of which are associated with cancer development and
progression [7]. ERM proteins are capable of interacting with
several cellular molecules that are strongly associated with
tumour progression, including CD43, CD44, ICAM-1,
ICAM-2, EGFR and MET [7, 8]. Several recent studies have
reported over-expression of ezrin as a marker of poor outcome
in a variety of human cancers [9–12]. The significance of
moesin immunoreactivity in tumour tissues, however, still
remains to be established.
RhoA, RhoB and Cdc42 are members of the Ras homolo-
gous (Rho) family of low molecular weight GTP-binding
proteins [13], and they act as major regulators of signal trans-
duction pathways affecting remodelling of the actin cytoskel-
eton. Initial studies investigating the role of RhoA in cellular
development revealed that over-expression of RhoA stimulates
actin polymerisation through the activation of diaphanous-
related formins (DRFs) and Rho-activated kinases (ROCKs).
A cooperation of RhoA, DRFs and ROCKs was found to
induce the formation of stress fibres, which are necessary for
maintaining cellular polarity and the proper shape of cells [14].
The specific functions of RhoB have not been described in
detail yet, but experimental studies have shown that RhoB is
down-regulated in human tumours and that its expression is
inversely related to tumour progression [15]. In addition, it was
found that Cdc42 is involved in increased cellular motility via
participation in the filopodia formation process [16].
The significance of ERM and Rho protein immunoreactiv-
ity in breast carcinogenesis and the impact on long-term
survival has so far remained unclear. In this study, we inves-
tigated the prognostic value of ERM (ezrin, moesin) and Rho
(RhoA, RhoB and Cdc42) protein expression by immunohis-
tochemical analyses in 85 patients with stage II ductal BC. We
assessed the relationship between the sub-cellular localisation
of these proteins in conjunction with the clinical character-
istics of the patients studied. Additionally, we assessed the
correlation between ERM/Rho reactivity in BC specimens
and the status of receptors for the female sex hormones (i.e.,
ER and PgR) and HER-2. Since the treatment protocol for
patients with stage II BC is still under debate, it is imperative
to establish new immunohistochemical markers for the strat-
ification of patients with stage II BC and, thus, to facilitate
personalised treatment tailored to tumour aggressiveness.
2 Material and methods
2.1 Patients
Tissue samples were obtained from 85 patients treated rad-
ically for stage II ductal breast cancer (BC), diagnosed
between 1993 and 1994 in the Lower Silesian Oncology
Centre in Wroclaw, Poland. The median age of the patients
was 55.6 years. The patients were selected based on the
availability of tissues. They were not stratified for preoper-
ative or pathological prognostic factors. All patients under-
went surgery (Madden mastectomy) with or without
adjuvant treatment. Cancer-specific overall survival
(CSOS) and disease-free survival (DFS) rates were estab-
lished for all patients. The total number of patients included
was stipulated by the single series performed by our insti-
tution, the follow-up period of 15 years, and the highly
homogeneous characteristics of the tumours selected (ductal
invasive breast cancer, G2 and G3, clinical stage II accord-
ing to UICC, Madden mastectomy). Also, the patients were
relatively young, which is due to the fact that the average
life expectancy and healthy life span in Poland in the period
1993–1994 were lower than those in e.g. Western Europe.
Detailed characteristics of the patient cohort are listed in
Table 1. The study was approved by the Institutional
Review Board of the Wroclaw Medical University, Poland.
2.2 Tumour samples
Tumour specimens were fixed in 10 % buffered formalin and
embedded in paraffin. All haematoxylin and eosin stained
sections were examined by two pathologists. Due to the
absence of a population-based BC screening at the time this
study was initiated, the size of the primary tumours was
different from the detriment of the value of other, e.g.
European countries. The median tumour size was also deter-
mined by the inclusion of a homogeneous group of clinical
stage II BC (see above). Tumour stages were assessed accord-
ing to the TNM classification system [17]. The tumour grades
were estimated according to the Bloom-Richardson protocol,
with the Elston and Ellis [18] modification (Table 1).
2.3 Immunohistochemistry
Immunohistochemical analyses were performed retrospec-
tively on tissue samples collected for routine diagnostic
182 A. Halon et al.
purposes. Formalin-fixed, paraffin embedded tissue sections
were freshly prepared (4 μm). Immunohistochemistry was
performed as previously described [19–21] using the follow-
ing antibodies diluted in Antibody Diluent, Background
Reducing (DakoCytomation, Poland): anti-ezrin (1:150, clone
4A5 mouse monoclonal, Chemicon International, Billerica,
USA), anti-moesin (1:100, Sc-6410, goat polyclonal, Santa
Cruz Biotechnology, Santa Cruz, USA), anti-RhoA (1:100,
Sc-179, rabbit polyclonal, Santa Cruz Biotechnology), anti-
RhoB (1:100, Sc-180, rabbit polyclonal, Santa Cruz
Biotechnology) and anti-Cdc42 (1:50, Sc-87, rabbit polyclon-
al, Santa Cruz Biotechnology). For the detection of the oes-
trogen receptor, an optimally pre-diluted mouse monoclonal
antibody (clone 1D5, DakoCytomation, Denmark) was used,
and for the detection of the progesterone receptor, an optimally
pre-diluted mouse monoclonal antibody (clone PgR636,
DakoCytomation, Denmark) was used. For HER-2 detection,
a semi-quantitative diagnostic immunohistochemical test was
used (HercepTest™Kit, K5207, DakoCytomation, Denmark).
The tissue sections were incubated with antibodies for 1 h at
room temperature. Subsequent incubations involved biotiny-
lated antibodies (15min, room temperature) and a streptavidin-
biotinylated peroxidase complex (15 min, room temperature)
(LSAB+, HRP, DakoCytomation, Poland). NovaRed (Vector
Laboratories, UK) was used as a chromogen (10 min, at room
temperature). All sections were counterstained with Meyer’s
haematoxylin. In each case control reactions were included, in
which the specific antibody was substituted by a Primary
Mouse Negative Control (DakoCytomation, Poland).
2.4 Evaluation of immunohistochemical reaction intensities
The intensities of the immunohistochemical reactions were
estimated independently by two pathologists. In order to
evaluate the expression of the proteins analysed, a semi-
quantitative scale of the ImmunoReactive Score (IRS), with
the author’s own modifications, was applied [22], in which
the intensity of the colour reaction and the percentage of
positive cells were both taken into account. The final, inte-
grated scores ranged from 0 to 12. The author’s IRS mod-
ification only involved the percentage of positive cells. This
is presented in Table 2. Cases with expression scores rang-
ing between 0 and 2 in the IRS scale were considered
negative. For each of the analysed proteins (except moesin),
next to a predominant cytoplasmic localisation, additional
sub-cellular localisations were observed. Ezrin was found to
display both membranous and nuclear localisations. RhoA
and Cdc42 were also found to be located in the nuclei of the
cells, and RhoB was found to be located in both the cell
membrane and the perinuclear zone. In addition, all the
analysed proteins were found to be present in the stromal
compartments of the tumours and in its blood vessels. A
three-step scale (SS, stromal score; BVS, blood vessel
Table 1 Patient and tumour characteristics
Characteristics No. (%)a
All patients 85 (100)





Invasive ductal BC 85 (100)
TNM stage according to UICC
II A 34 (40)
II B 51 (60)




















Negative (0,1+,2+) 66 (77.6)
Positive (3+) 19 (22.4)
a Percentages in the groups may not sum to 100 % due to rounding off
b Some patients received more than one special treatment
Table 2 Procedure for evaluation of ERM and Rho protein
expression
IRS (ImmunoReactive Score) modified by the authorsa
Percentage of positive cells Points Intensity of reaction Points
No positive cells 0 No reaction 0
<25 % positive cells 1 Weak colour reaction 1
25–50 % positive cells 2 Moderate intensity 2
51–75 % positive cells 3 Intense reaction 3
>75 % positive cells 4
a IRS score (ImmunoReactive Score) according to Remmele et al. [22]
modified by the authors
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score), including the intensity of the colour reaction and the
percentage of stained tissue or blood vessels (SS or BVS 0:
no reaction; 1: weak reaction; 2: moderately positive reac-
tion; 3: strongly positive reaction), was used for the evalu-
ation of stromal and blood vessel reactivity.
The evaluation of oestrogen and progesterone receptor
expression was performed using standard methods. The
staining intensity (0–3 scale) and proportion of positive cells
(0–5 scale) were reported, and the Allred score that com-
bines the two was calculated. The HER-2 status was evalu-
ated using a FDA-approved scoring system of 0, 1+, 2+
and 3+ (0: no immunostaining; 1+: weak immunostaining,
less than 30 % of the tumour cells; 2+: complete membra-
nous reactivity, either uniform or weak in at least 10 % of
the tumour cells; 3+: uniform intense membranous staining
in at least 30 % of the tumour cells).
2.5 Statistical analyses
Statistical analyses were performed using the Statistica 9.1
software package (StatSoft Inc., Tulsa, OK, USA). Disease-
free survival (DFS) was defined as the time between the
primary surgical treatment and date of relapse or death,
whichever occurred first. DFS was censored at the last
follow-up for patients who survived without disease recur-
rence. Cancer-specific overall survival (CSOS) was defined
as the time between the primary surgical treatment and
cancer-associated death, and was censored at the last
follow-up for surviving patients. The χ2 and Spearman rank
correlation were used to analyse associations between
ERM/Rho protein expression parameters and clinicopatholog-
ical parameters. The overall survival rate was estimated by the
Kaplan-Meier method and the log-rank test. P values <0.05
were considered statistically significant.
3 Results
3.1 Ezrin and moesin immunostaining in breast cancer
specimens
Ezrin protein expression was detected in all breast cancer
(BC) cases with a mean IRS of 8.88. The dominant sub-
cellular localisation of ezrin was cytoplasmic (Fig. 1a). Co-
expression of ezrin in the cellular membrane (20 cases,
23.53 %) (Fig. 1b) and the nucleus (27 cases, 31.76 %)
(Fig. 1c) was also observed. Immunostaining of moesin
revealed only a cytoplasmic reaction with a mean IRS of
3.69 (Fig. 1d). Interestingly, microscopic analyses also
revealed ezrin and moesin expression in the stromal com-
partment of the BC tumour specimens and in its blood
vessels (Table 3).
3.2 RhoA, RhoB and Cdc42 immunostaining in breast
cancer specimens
RhoA, RhoB and Cdc42 protein expression was detected in




of ezrin and moesin proteins. a
cytoplasmic localisation of
ezrin (ImmunoReactive Score
(IRS) 12, ×200, haematoxylin);
b membranous localisation of
ezrin (IRS 12, ×100,
haematoxylin); c nuclear
localisation of ezrin (IRS
8, ×100, haematoxylin); d
cytoplasmic localisation of
moesin (IRS 9, ×100,
haematoxylin)
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localisation of these proteins was cytoplasmic (Fig. 2a and
b). For RhoA and Cdc42, co-expression in the cytoplasm
and the nucleus was observed (70 cases, 82.35 %, and 6
cases, 7.1 %, respectively) (Fig. 2c and d). Immunostaining
of RhoB revealed an additional sub-cellular localisation in
the cellular membrane (14 cases, 16.47 %) and the perinu-
clear space (24 cases, 28.24 %) (Fig. 2e and f). Similar to the
ERM protein family (i.e., ezrin and moesin), RhoA, RhoB
and Cdc42 immunoreactivity was also observed in the stro-
mal compartment of the breast tumour samples and its blood
vessels (Table 3).
3.3 Relationship between ERM/Rho expression and status
of steroid receptors and HER-2 reactivity
No relationship was observed between ERM/Rho protein
expression and ER, PgR or HER-2 reactivity in the breast
cancer specimens (Table 4). Interestingly, however, we ob-
served a significant correlation between a decreased ezrin
expression (BVS 0, 1, 2 versus BVS 3) and a positive PgR
status in the tumour blood vessels (P=0.028). In addition,
we observed a correlation between low ezrin expression and
HER-2 over-expression in the tumour blood vessels. This
latter observation, however, was not statistically significant
(P=0.059).
3.4 Relationship between ezrin and moesin expression
and clinicopathological parameters
Analysis of ezrin and moesin protein expression and patient
clinicopathological parameters revealed significant correla-
tions between protein expression and the presence of lymph
node metastases in the tumour compartments (P=0.047 and
P=0.038, respectively). We also observed a correlation be-
tween an increased ezrin immunoreactivity and the UICC
stage (IIA versus IIB). This latter correlation was, however,
not statistically significant. No significant relationships be-
tween ezrin or moesin expression and grading, tumour size
and age at diagnosis were observed (Table 4). Notably, nuclear
expression of ezrin was observed in 47.22 % of the cases with
lymph node metastases, compared to 18.37 % in patients
without nodal metastases (P=0.004). We also found that
nuclear expression of ezrin was associated with grade 3 (G3)
breast cancer tumours (P=0.015), thus confirming a potential
role of nuclear ezrin immunodistribution in tumour develop-
ment. No significant associations were observed between
ezrin and moesin expression in the stromal compartments
and tumour blood vessels and clinicopathological parameters,
although a weak correlation between enhanced immunore-
activity of ezrin in the stroma and the postmenopausal
status of patients was noted (P=0.042) (Table 4).
Table 3 Characteristics of ERM
and Rho protein expression in
the tumour and stromal com-
partments in breast cancer cases
aMean value and standard
deviation
Parameters which are commented
in text are underlined with bold
text
Parameters of expression Number of patients (percentage)
EZRIN MOESIN RhoA RhoB Cdc42
Quantitative parameters
Lack of expression (IRS≤2) 0 (0) 23 (27.1) 0 (0) 0 (0) 0 (0)
Positive reactivity (IRS>2) 85 (100) 62 (72.9) 85 (100) 85 (100) 85 (100)
% of positive cellsa 3.71±0.484 2.44±1.220 3.56±0.544 3.54±0.547 3.18±0.99
Intensity of reactiona 2.38±0.511 1.45±0.592 1.89±0.489 2.09±0.503 1.78±0.68
IRS Scorea 8.88±2.51 3.69±2.65 6.74±2.09 7.42±2.25 5.96±3.32
Subcellular topography in cancer cells
Cytoplasmic 85 (100) 62 (72.9) 85 (100) 85 (100) 85 (100)
Membranous 20 (23.5) 0 (0) 0 (0) 14 (16.5) 0 (0)
Nuclear 27 (31.8) 0 (0) 70 (82.4) 0 (0) 6 (7.1)
Perinuclear 0 (0) 0 (0) 0 (0) 24 (28.2) 0 (0)
Stromal expression
SS 0 0 (0) 27 (31.8) 0 (0) 0 (0) 0 (0)
SS 1 27 (31.8) 54 (63.5) 66 (77.7) 66 (77.7) 59 (69.4)
SS 2 57 (67.1) 4 (4.71) 19 (22.3) 19 (22.3) 26 (30.6)
SS 3 1 (1.2) 0 (0) 0 (0) 0 (0) 0 (0)
Tumour blood vessel expression
BVS 0 0 (0) 21 (24.7) 0 (0) 0 (0) 0 (0)
BVS 1 13 (15.3) 50 (58.8) 30 (35.3) 10 (11.8) 47 (55.3)
BVS 2 69 (81.2) 14 (16.5) 55 (64.7) 75 (88.2) 38 (44.7)
BVS 3 3 (3.5) 0 (0) 0 (0) 0 (0) 0 (0)
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3.5 Relationship between RhoA, RhoB and Cdc42
expression and clinicopathological parameters
Over-expression of RhoA, RhoB and Cdc42 in the
tumours was found to be associated with the presence
of lymph node metastases (P=0.024, P=0.004 and P=
0.047, respectively). Additionally, we observed a statis-
tically significant correlation between elevated RhoB
expression and stage IIB according to the UICC (P=
0.033). Additional analyses of the sub-cellular distribu-
tion of RhoA revealed that a nuclear localisation was
associated with a lack of nodal metastases (P=0.008)
and low grading (P=0.055). Similarly, the nuclear to-
pography of Cdc42 and perinuclear localisation of
RhoB were both correlated with a lack of lymph node
metastases in univariate analyses (P=0.048 and P=
0.001, respectively). No significant relationships were
observed between the expression of RhoA, RhoB and
Cdc42 and other clinicopathological parameters, includ-
ing tumour size, grade, age at diagnosis and menopaus-
al status (Table 4).
Expression analyses of the Rho proteins in the stromal
compartments and tumour blood vessels in the BC specimens





of Rho proteins. a cytoplasmic
localisation of RhoA (IRS
12, ×200, haematoxylin); b
cytoplasmic localisation of
Cdc42 (IRS 12, ×100,
haematoxylin); c nuclear
localisation of RhoA (IRS
9, ×100, haematoxylin); d
nuclear localisation of Cdc42
(IRS 8, ×200, haematoxylin);
e membranous localisation of
RhoB (IRS 8, ×100,
haematoxylin); f perinuclear
localisation of RhoB (IRS
9, ×100, haematoxylin)
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RhoA in the tumour stromal compartment was correlated
with the presence of lymph node metastases (P=
0.011). Furthermore, the low level of Cdc42 observed
in the tumour stromal compartment was correlated with
a postmenopausal status (P=0.018). In keeping with this
latter finding, elevated Cdc42 reactivity in the tumour
blood vessels was significantly correlated with the pre-
menopausal status of patients (P=0.026). Older women
were characterised by a decreased expression of Cdc42
in the tumour blood vessels (Table 4).
3.6 Ezrin and moesin immunoreactivity and patient survival
Survival analyses did not reveal any prognostic significance
of ezrin and moesin protein expression in BC patients. Also,
no impact of the IRS of both proteins and their sub-cellular
localisations on cancer-specific overall survival (CSOS) and
disease-free survival (DFS) was noted (Fig. 3a).
3.7 RhoA, RhoB and Cdc42 immunoreactivity and patient
survival
Survival analyses did reveal a significant association be-
tween the over-expression of RhoB in the stromal compart-
ment and a better patient outcome (P=0.0106) (Fig. 3c).
Interestingly, this analysis did not reveal any impact of the
sub-cellular distribution of RhoA. Correlation analyses be-
tween RhoA, RhoB and Cdc42 protein expression and pa-
tient survival did not reveal any statistically significant
relationships (Fig. 3b and d).
Table 4 Correlation between ERM/Rho expression and clinicopathological parameters
CLINICOPATHOLOGICAL PARAMETERS









IRSb 0.337 0.118 0.462 0.151 0.047 0.058 0.186 0.115 0.072 0.004
Membranousc 0.527 0.091 0.382 0.923 0.383 0.961 0.523 0.582 0.872 0.665
Nuclearc 0.070 0.170 0.646 0.133 0.004 0.730 0.015 0.964 0.524 0.080
Stromal (SS)c 0.441 0.441 0.560 0.354 0.947 0.113 0.575 0.376 0.042 0.132
Blood vessels (BVS)c 0.117 0.028 0.059 0.092 0.124 0.470 0.630 0.738 0.415 0.507
MOESIN
IRSb 0.944 0.644 0.473 0.315 0.038 0.460 0.770 0.812 0.748 0.884
Stromal (SS)c 0.354 0.236 0.252 0.578 0.375 0.177 0.344 0.346 0.480 0.483
Blood vessels (BVS)c 0.588 0.173 0.083 0.606 0.390 0.541 0.252 0.531 0.390 0.488
RhoA
IRSb 0.730 0.928 0.928 0.292 0.024 0.845 0.093 0.528 0.691 0.333
Nuclearc 0.463 0.243 0.437 0.092 0.008 0.561 0.055 0.517 0.306 0.001
Stromal (SS)c 0.298 0.527 0.061 0.644 0.011 0.606 0.394 0.400 0.155 0.038
Blood vessels (BVS)c 0.398 0.601 0.414 0.531 0.149 0.268 0.351 0.587 0.259 0.191
RhoB
IRSb 0.932 0.232 0.990 0.690 0.004 0.033 0.795 0.182 0.078 0.123
Membranousc 0.482 0.272 0.167 0.481 0.065 0.603 0.603 0.478 0.524 0.482
Perinuclearc 0.011 0.038 0.110 0.422 0.001 0.522 0.344 0.346 0.165 0.028
Stromal (SS)c 0.133 0.527 0.017 0.644 0.477 0.200 0.200 0.210 0.155 0.568
Blood vessels (BVS)c 0.425 0.425 0.678 0.221 0.309 0.221 0.067 0.489 0.305 0.479
Cdc42
IRSb 0.446 0.241 0.247 0.787 0.047 0.804 0.313 0.993 0.253 0.671
Nuclearc 0.614 0.386 0.690 0.526 0.048 0.563 0.181 0.293 0.489 0.313
Stromal (SS)c 0.504 0.147 0.510 0.537 0.152 0.053 0.924 0.087 0.018 0.187
Blood vessels (BVS)c 0.210 0.572 0.322 0.384 0.377 0.101 0.379 0.016 0.026 0.226
aP value of Spearman’s rank correlation
bP value of χ2
cP value of Fisher’s test
Statistically significant results (P values) are underlined with bold text
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4 Discussion
In this study, we investigated the expression of the ERM
(ezrin, moesin) and Rho (RhoA, RhoB, Cdc42) protein
families in a homogeneous group of patients with stage II
invasive ductal breast cancer (BC). In addition, we assessed
relationships between the sub-cellular localisation of these
proteins, clinicopathological parameters and patient survival
over a 15 year period. We also evaluated relationships
between ERM/Rho reactivities in BC specimens and the
status of steroid receptors and HER-2.
A correct sub-cellular localisation of the ERM and Rho
proteins is essential for their normal function. The predom-
inant localisation of all proteins analysed was cytoplasmic.
In addition, our study revealed several other ERM/Rho sub-
cellular topographies. Ezrin localisation was observed in
both the nucleus and the cellular membrane, whereas
moesin was only observed in the cytoplasm. RhoA and
Cdc42 were characterised by a nuclear localisation,
whereas RhoB was observed in the cellular membrane
and the perinuclear zone. Interestingly, the nuclear ex-
pression of RhoA and Cdc42, and the perinuclear to-
pography of RhoB, were strongly associated with a
lack of nodal metastases in our univariate analyses,
but this was not reflected in the Kaplan-Meier survival
analyses. Notably, however, the nuclear localisation of
ezrin was associated with the presence of nodal metas-
tases. We also observed that the nuclear localisation of
ezrin was strongly correlated with grade 3 BC tumours,
thus confirming the potential role of nuclear ezrin
immunodistribution in carcinogenesis.
To date, several sub-cellular ERM and Rho protein top-
ographies have been described. For ezrin, cytoplasmic,
membranous, nuclear and apical localisations have been
reported [9–12]. Moesin was almost exclusively found to
be located in the cytoplasm [23–25], with one study also
reporting this protein to be located in the cellular membrane
[24]. The latter was not observed in our study. The RhoA
and RhoB sub-cellular localisation patterns reported in the
literature are limited to the cytoplasm [26–29], with only
one study reporting localisation in the cellular membrane
[29]. Interestingly, Cdc42 expression has only been ob-
served in the cytoplasm [30].
In this study, over-expression of ERM and Rho proteins
in the tumour compartment of ductal BC was found to be





Fig. 3 Kaplan-Meier curves for cancer-specific overall survival
(CSOS) and disease-free survival (DFS) and selected ERM/Rho im-
munohistochemical parameters. No significant differences in DFS and
enhanced immunoreactivity of ezrin, RhoA and Cdc42 (a, b and d,
respectively) are observed. c Patients with over-expression of RhoB in
the stromal compartment exhibit an increased CSOS (P=0.0106)
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metastases, thus confirming the role of these molecules in
BC progression. Similar results, indicating that cytoplasmic
ezrin expression may act as a negative prognostic factor,
were reported by Sarrio et al. [10], where the cytoplasmic
expression of ezrin was strongly associated with lymph
node metastases. In their study, Sarrio et al. specifically
showed that differential ezrin localisations, rather than total
protein levels, were correlated with a more aggressive be-
haviour of BC tumours. The change in ezrin distribution
from the apical part of the membrane to either the complete
membrane, or to the cytoplasm, has been associated with de-
differentiation of BC cells and unfavourable clinical features
in invasive BC [10]. It is worth noting that cytoplasmic ezrin
is thought to exist in a dormant, inactive conformation,
which is unable to associate with cellular membrane pro-
teins and the actin cytoskeleton [7]. This, in turn, suggests
that an altered ezrin sub-cellular distribution may be respon-
sible for the de-regulation of ezrin-mediated cytophysiolog-
ical processes. Intriguingly, we also observed complete
membranous ezrin expression in 20 ductal BC cases
(23.53 %). Because of the small patient cohort size, howev-
er, no significant prognostic value could be deduced. The
possible biochemical mechanism, which may explain this
phenomenon, relates to ezrin redistribution to the entire
cellular membrane (not to the apical part), and may be
influenced by external growth factors. Following stimula-
tion, ezrin is present in an active form and, as such, can bind
to membrane proteins and the actin cytoskeleton to create
ezrin-rich cell membrane structures such as filopodia, which
are strongly associated with enhanced motility, invasion and
metastatic potential [31, 32]. To the best of our knowledge,
this is the first study to also describe a nuclear localisation of
ezrin in BC cells (27/85 cases, 31.76 %). Based on this
location, ezrin might also act as a transcriptional factor.
Consistent with our results, Charafe-Jauffret et al. [23]
reported immunoreactivity of moesin in the cytoplasm
of BC cells. Interestingly, they also observed moesin
expression in the stromal compartment and tumour
blood vessels, but the significance of this expression
was not investigated in detail.
Rho family proteins are involved in the regulation of
many different cellular processes, including migration, cell
cycle progression, exocytosis and apoptosis. RhoA, RhoB
and Cdc42 play a crucial role in the development of cancer,
being main factors responsible for cellular motility and loss
of adhesion. Expression of these proteins has been studied
in many cancers, and various relationships have been
revealed that clearly demonstrate the important role of Rho
GTPases in carcinogenesis [26–28, 33, 34]. In our study,
over-expression of RhoA, RhoB and Cdc42 was found to be
strongly associated with the presence of lymph node metas-
tases. Additionally, we observed a statistically significant
correlation between an increased immunoreactivity of RhoB
and stage IIB BC according to the UICC. Similar results on
over-expression of Rho GTPases in breast cancer were
reported by Fritz et al. [35]. In this latter study, RhoA,
RhoB and Cdc42 protein levels were significantly elevated
in BC samples compared to healthy breast tissues originat-
ing from the same individuals [35]. Intriguingly, RhoA and
RhoB reactivity was found to significantly increase with the
proliferation index and grading of the tumours, but the
authors did not correlate Rho GTPase expression with clin-
icopathological parameters, such as nodal status or patient
survival. In oesophageal squamous cell carcinoma, RhoA
over-expression has significantly been correlated with the
TNM stage, lymphatic and blood vessel invasion [27].
Moreover, 5-year survival rates were found to be lower in
patients with enhanced reactivity of RhoA. A prognostic
value of RhoA has also been observed in hepatocellular
carcinoma, where a strong expression predicts a shorter
survival rate [28]. Interestingly, Dittert et al. [26] revealed
that RhoA expression in ductal pancreatic adenocarcinoma
does not correlate with TNM classification, and that over-
expression of this protein is strongly associated with a better
prognosis. Furthermore, they observed stromal expression
of RhoA, but did not correlate this with clinicopatho-
logical parameters. According to Pan et al. [36], a high
expression of RhoA mRNA was significantly associated
with advanced TNM classification and a low grade of
histological differentiation. However, RhoB and Cdc42
mRNA levels did not correlate with the clinicopatholog-
ical parameters studied. In retinoblastoma it was found
that Cdc42 reactivity, measured by immunohistochemis-
try and Western blotting, had no prognostic value, and
that over-expression of Cdc42 did not correlate with
tumour invasion or histological differentiation [37]. In
our study, an elevated expression of Cdc42 was found
to be associated with nodal metastases, but qualitative
analyses revealed paradoxical results, i.e., nuclear local-
isation of Cdc42 served as a good prognostic factor.
In summary, we report a first integrated expression anal-
ysis of different ERM and Rho protein family members in
ductal breast cancer. ERM/Rho immunoprofiles and detailed
sub-cellular localisation patterns may facilitate the predic-
tion of lymph node metastases in ductal BC patients. No
relationships were found between ERM/Rho expression and
ER, PgR or HER-2 reactivity in BC cells. Also, survival
analyses did not reveal a prognostic significance of
ERM/Rho protein expression, except for RhoB over-
expression in the stromal compartment of tumours, which
was found to be associated with a better patient survival.
Clearly, additional studies on extended patient cohorts are
required to confirm our findings. Also, additional studies are
needed to firmly establish the clinicopathological implica-
tions of ezrin, moesin, RhoA, RhoB and Cdc42 expression
in breast carcinogenesis.
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